Neurofilament light chain (NfL) released from damaged neurons requires crossing the BBB to appear in blood. Two mechanisms can elevate blood NfL: (1) enhanced caveolin-mediated transcytosis due to endothelial Wnt/β-catenin signaling loss (active transport dysfunction, earlier disease) versus (2) passive paracellular leakage from severe barrier disruption (advanced disease). The ratio of blood NfL rise relative to CSF NfL rise may distinguish these mechanisms. This hypothesis integrates endothelial signaling dysfunction with neurodegeneration biomarkers but requires simultaneous CSF and serum sampling, complicating clinical implementation.
Curated pathway from expert analysis
flowchart TD
A["Neurofilament Light<br/>Chain (NEFL)"]
B["Blood-Brain Barrier<br/>Transcytosis"]
C["Serum vs CSF<br/>NFL Ratio"]
D["Active Axonal<br/>Degeneration"]
E["Cognitive<br/>Decline"]
F["CAV1 (Caveolin-1)<br/>Endothelial Caveolae"]
G["Pericyte<br/>Coverage"]
A --> B
B --> C
F --> B
G --> B
D --> A
D --> E
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for NEFL yet. Search RCSB →
Median TPM across 13 brain regions for NEFL, CAV1 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NEFL, CAV1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If active transcytosis drives NfL into CSF, then inhibition of caveolin-1-mediated transcytosis (e.g., by caveolin-1 siRNA or caveolin scaffolding domain peptides) will reduce CSF NfL in model systems | In an ex vivo human BBB model (iPSC-derived pericyte-laden microfluidic device), caveolin-1 inhibition reduces transendothelial NfL flux by 50-70% (measured by | — no observation — | pending | 0.69 |
| If CSF/serum NfL ratio distinguishes active transcytosis from passive BBB breakdown, then high CSF/serum NfL will correlate with elevated caveolin-1 (transcytosis marker) and normal Qalb (intact parac | In matched patient groups (n≥30 transcytosis dysfunction, n≥30 paracellular leakage, n≥30 controls), CSF/serum NfL ratio successfully discriminates transcytosis | — no observation — | pending | 0.75 |